Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients

NCT00642928 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

108

Enrollment

OTHER

Sponsor class

Conditions

Excessive Daytime Sleepiness
Parkinson's Disease

Interventions

DRUG: Placebo
DRUG: BF 2.649 5 mg
DRUG: BF 2.649 10 mg
DRUG: BF 2.649 20 mg
DRUG: BF 2.649 40 mg

Sponsor

Bioprojet